Organophosphate Toxicity

Organophosphate toxicity in dogs is a serious and potentially life-threatening poisoning that occurs when canines are exposed to organophosphate compounds found in many insecticides, pesticides, and some flea control products. These chemicals work by inhibiting acetylcholinesterase, an enzyme essential for normal nerve function, leading to overstimulation of the nervous system that can cause severe symptoms including excessive salivation, muscle tremors, seizures, and respiratory failure. Organophosphates were once widely used in agricultural and household settings, and while their use has declined due to safety concerns, they remain present in many products that dogs may encounter in outdoor environments.

The mechanism of organophosphate toxicity involves irreversible binding to acetylcholinesterase at nerve synapses. Under normal conditions, this enzyme breaks down acetylcholine after it has transmitted a nerve signal, allowing the nerve to reset for the next impulse. When organophosphates inactivate this enzyme, acetylcholine accumulates continuously at nerve junctions, causing uncontrolled and persistent nerve stimulation. This overstimulation affects the entire body but is particularly dangerous for the respiratory system, where it can cause bronchospasm and excessive secretions that impair breathing. The effects can progress rapidly from mild symptoms to life-threatening respiratory failure within hours of exposure.

The impact of organophosphate toxicity on a dog's health depends on the specific compound involved, the dose absorbed, and the route of exposure. Dogs can be poisoned through oral ingestion of treated plants or contaminated food, dermal absorption through the skin after walking through treated areas or contact with concentrated products, and less commonly through inhalation of sprays or vapors. Smaller dogs are at greater risk of severe toxicity because a given amount of poison represents a larger dose relative to their body weight. The effects are cumulative with repeated exposures, and some individuals are more sensitive than others based on their individual enzyme levels and metabolism.

Treatment of organophosphate toxicity is highly effective when initiated promptly, making this a true veterinary emergency where minutes matter. The antidote atropine blocks the effects of accumulated acetylcholine and can rapidly reverse many symptoms. Pralidoxime can reactivate acetylcholinesterase if given before the enzyme-inhibitor bond becomes permanent, typically within twenty-four to forty-eight hours of exposure. With aggressive treatment, many dogs recover fully from organophosphate poisoning. However, delayed treatment or massive exposures carry a guarded to poor prognosis, and some dogs experience intermediate syndrome or delayed neurological effects. Prevention through careful management of pesticide use and storage is far preferable to treating poisoning after it occurs.

The primary cause of organophosphate toxicity in dogs is exposure to pesticides and insecticides containing organophosphate compounds. Common sources include garden and lawn insecticides such as malathion and diazinon, agricultural pesticides used on crops, some older formulations of flea and tick products, and certain products used for fly control around homes and livestock facilities. Dogs may encounter these chemicals when walking through recently treated lawns or gardens, by drinking water contaminated with runoff from treated areas, through grooming after dermal contact, or by directly ingesting pesticide products or treated materials. Storage areas containing these products pose a risk if dogs gain access to concentrated formulations.

Genetic factors do not predispose dogs to organophosphate toxicity in the traditional sense, but individual variation in acetylcholinesterase levels and metabolic capacity affects sensitivity. Some dogs may have naturally lower baseline enzyme activity, making them more vulnerable to inhibition from a given exposure. Age affects susceptibility, with very young and very old dogs potentially having less efficient detoxification mechanisms. Dogs with pre-existing liver disease may metabolize and eliminate organophosphates less efficiently, prolonging exposure. While no specific breed sensitivity has been established for organophosphates, any dog with compromised liver or nervous system function may be at increased risk of severe effects.

Environmental and lifestyle factors significantly influence the risk of organophosphate exposure. Dogs living in agricultural areas face higher exposure risks from crop spraying and farm chemical use. Rural dogs that roam freely may encounter treated fields or discarded pesticide containers. Suburban dogs are at risk from lawn and garden treatments, particularly if neighbors or professional services apply pesticides without the dog owner's knowledge. Dogs that hunt or scavenge may consume poisoned prey animals or eat treated bait intended for pests. Seasonal factors play a role, with exposure risk highest during growing seasons when insecticides are most heavily applied.

Risk factors for severe organophosphate toxicity include exposure to concentrated products rather than diluted applications, large doses relative to body weight, dermal exposure that continues uninterrupted allowing ongoing absorption, and delayed recognition and treatment. Small dogs are at higher risk because they receive proportionally larger doses from any given exposure. Dogs that groom contaminated fur ingest additional toxin. Concurrent exposure to other anticholinesterase compounds, including some medications and carbamate insecticides, can have additive effects. Hot weather increases dermal absorption and metabolic rate, potentially worsening toxicity.

The mechanism of organophosphate toxicity centers on inhibition of acetylcholinesterase at three types of cholinergic receptors. At muscarinic receptors in smooth muscle and glands, inhibition causes excessive salivation, lacrimation, urination, defecation, miosis (constricted pupils), and bradycardia, remembered by the mnemonic SLUDGE. At nicotinic receptors in skeletal muscle, effects include muscle fasciculations, weakness, and eventually paralysis. Central nervous system effects include anxiety, seizures, and respiratory depression. The combination of bronchospasm from muscarinic effects, respiratory muscle weakness from nicotinic effects, and central respiratory depression creates a triple threat to breathing that makes respiratory failure the most common cause of death in organophosphate poisoning.

Early warning signs of organophosphate toxicity in dogs typically appear within minutes to hours of exposure, depending on the route and magnitude of exposure. Initial symptoms may include subtle restlessness, anxiety, or unusual behavior as the dog begins to feel the effects of cholinergic overstimulation. Mild drooling or excessive licking may be noticed before more dramatic salivation develops. Some dogs show increased frequency of urination or defecation early in the course. Pinpoint pupils visible in normal lighting conditions provide an early clue to cholinergic toxicity. Dogs may appear uncomfortable or display mild muscle twitching before progressing to more obvious tremors.

Common symptoms of organophosphate poisoning are characterized by the classic cholinergic toxidrome affecting multiple organ systems. Profuse salivation is often one of the most striking features, with some dogs producing so much saliva that it streams from their mouths. Excessive tearing causes watery eyes and wet facial fur. Vomiting and diarrhea occur as gastrointestinal smooth muscle is overstimulated. Frequent urination, sometimes with loss of bladder control, results from bladder muscle contraction. These symptoms constitute the muscarinic effects and may be accompanied by slowed heart rate and constricted pupils that respond poorly to light.

Behavioral changes in organophosphate toxicity reflect central nervous system involvement. Dogs may appear anxious, agitated, or restless as the toxicity begins. Disorientation and confusion develop as the condition progresses. Some dogs vocalize excessively or show dramatic personality changes. As toxicity worsens, depression and lethargy replace agitation. Severe cases progress to stupor and coma. Seizures may occur in moderate to severe poisoning and can be prolonged or recurrent without treatment. These central nervous system effects compound the danger by impairing the dog's protective reflexes and ability to clear respiratory secretions.

Physical signs observable during examination include the characteristic pinpoint pupils that are a hallmark of cholinergic toxicity. Muscle fasciculations present as visible rippling or twitching under the skin, particularly noticeable over large muscle groups. Tremors progress to more generalized and uncontrollable shaking. Muscle weakness, especially noticeable in the hindlimbs initially, can progress to paralysis. Respiratory abnormalities include labored breathing, wheezing from bronchospasm, and gurgling sounds from excessive secretions in the airways. The heart rate may be slow initially but can become rapid as the dog struggles to compensate. Pale or bluish gums indicate inadequate oxygenation.

Symptom progression in organophosphate toxicity can be rapid and dramatic. The onset and pace depend on the route of exposure, with ingestion of concentrated products causing the most rapid progression, often within fifteen to thirty minutes. Dermal exposure may have a more gradual onset over hours as absorption continues. Initial mild symptoms can escalate to life-threatening respiratory distress within hours. Without treatment, the combination of bronchospasm, excessive respiratory secretions, respiratory muscle weakness, and central respiratory depression leads to respiratory failure. Some dogs that survive the acute phase may develop intermediate syndrome three to five days later, characterized by weakness of respiratory and proximal limb muscles.

Emergency symptoms requiring immediate veterinary attention include any suspected organophosphate exposure, even without visible symptoms initially. Difficulty breathing, characterized by labored respiration, gasping, extended neck, or bluish gum color, demands emergency care. Seizures require immediate intervention. Collapse or inability to stand indicates severe toxicity. Profuse uncontrollable salivation combined with other symptoms suggests significant poisoning. Muscle rigidity or severe tremors warrant emergency evaluation. Loss of consciousness is life-threatening. If organophosphate exposure is suspected based on known contact with pesticides, potential access to treated areas, or the classic symptom pattern, dogs should be transported immediately to a veterinary facility, taking care to minimize handlers' exposure to any contaminated fur.

Initial examination for suspected organophosphate toxicity focuses on recognizing the characteristic cholinergic toxidrome and stabilizing the patient. The veterinarian will gather history about potential pesticide exposures, including recent lawn treatments, access to gardens or agricultural areas, possible ingestion of products, and timeline of symptom development. Physical examination assesses the hallmark signs including pupil size, salivation, muscle fasciculations, respiratory status, and heart rate. Identification of the classic SLUDGE signs (salivation, lacrimation, urination, defecation, gastrointestinal distress, emesis) combined with nicotinic effects strongly suggests organophosphate or carbamate poisoning. Stabilization, particularly of respiratory function, takes priority over diagnostic workup.

Diagnostic tests for organophosphate toxicity aim to confirm the diagnosis and assess the degree of exposure. Measurement of blood cholinesterase activity is the gold standard for confirming organophosphate poisoning, with levels typically reduced to less than fifty percent of normal in symptomatic cases. However, results may not be available immediately, and treatment should not be delayed awaiting confirmation. Baseline bloodwork including complete blood count and chemistry panel assesses overall health and identifies any concurrent conditions. Blood gas analysis evaluates oxygenation and ventilation status in severely affected dogs. Response to atropine treatment serves as a therapeutic trial that supports the diagnosis when cholinergic signs improve.

Differential diagnosis for organophosphate toxicity includes other causes of similar cholinergic symptoms. Carbamate insecticide poisoning produces nearly identical signs but is generally shorter in duration because carbamates reversibly bind acetylcholinesterase. Certain mushroom species containing muscarine cause the SLUDGE syndrome without nicotinic effects. Some medications, plants, and other toxins can produce similar presentations. Other causes of seizures must be considered if that is the predominant sign. The history of potential pesticide exposure, combined with the full constellation of muscarinic and nicotinic signs, typically allows clinical differentiation from other conditions.

Diagnosis confirmation relies on the combination of compatible history, characteristic clinical signs, reduced blood cholinesterase activity, and response to antidotal therapy. If a product container or sample is available, identification of the specific organophosphate compound helps guide treatment intensity and prognosis. Poison control centers can assist with product identification and toxicity assessment. In cases where the history is unclear, dramatic improvement following atropine administration strongly supports the diagnosis. Postmortem confirmation in fatal cases can be obtained through tissue cholinesterase measurement and toxicological analysis. For surviving dogs, repeated cholinesterase measurements showing gradual recovery over days to weeks confirms the diagnosis and indicates safe enzyme regeneration.

Emergency treatment for organophosphate toxicity begins with decontamination and stabilization. For dermal exposure, contaminated fur must be thoroughly washed with mild dish soap and copious water while protecting handlers from exposure through gloves and protective clothing. Clipping fur may be necessary for heavily contaminated dogs. For recent oral ingestion in alert, stable dogs, induced vomiting may be considered if less than one to two hours have passed. Activated charcoal is administered to bind unabsorbed toxin in the gastrointestinal tract. Airway management takes priority if respiratory distress is present, including suctioning secretions, providing supplemental oxygen, and potentially intubation and mechanical ventilation in severe cases.

Medical management centers on antidotal therapy with atropine and pralidoxime. Atropine is a competitive antagonist at muscarinic receptors and rapidly reverses the SLUDGE symptoms. Initial doses are given intravenously and repeated as needed to control salivation and respiratory secretions without causing excessive atropinization. Large cumulative doses may be required, far exceeding typical therapeutic doses. Pralidoxime (2-PAM) reactivates acetylcholinesterase before the enzyme-inhibitor bond ages and becomes permanent. It must be given within twenty-four to forty-eight hours of exposure for maximum benefit. Pralidoxime primarily addresses nicotinic effects including muscle weakness and is given by slow intravenous infusion. The combination of both antidotes provides more complete reversal than either alone.

Surgical intervention is not typically applicable to organophosphate toxicity treatment. However, severely affected dogs may require intensive supportive procedures. Intubation and mechanical ventilation are necessary for dogs with respiratory failure that cannot maintain adequate oxygenation and ventilation spontaneously. Thorough and repeated bathing may be considered a procedural intervention when significant dermal contamination is present. In extremely rare cases, lipid emulsion therapy has been used experimentally for fat-soluble organophosphates, though this is not standard treatment.

Supportive care addresses the many complications that can arise during organophosphate toxicity. Intravenous fluid therapy maintains hydration and blood pressure. Seizure control with diazepam or other anticonvulsants is essential for dogs experiencing seizures, with some preferring diazepam specifically because it also addresses anxiety and has neuroprotective effects. Temperature regulation is important as severely affected dogs may develop hypothermia or hyperthermia. Nutritional support through feeding tubes or parenteral nutrition sustains dogs requiring prolonged recovery. Turning recumbent patients prevents pressure sores. Eye lubrication protects against corneal damage if the blink reflex is impaired.

Alternative and complementary treatments have limited application in acute organophosphate toxicity, where specific antidotal therapy is paramount. However, some supportive measures may be employed. Lipid emulsion therapy has shown promise in some case reports and experimental settings for certain lipophilic organophosphates. Once stabilized, physical therapy may help dogs recovering from prolonged weakness. There is no proven role for other alternative therapies in acute poisoning, and focus must remain on rapid administration of proven antidotes and intensive supportive care.

Treatment decisions depend on severity of presentation, time since exposure, and response to initial therapy. Mild cases with minimal symptoms may respond quickly to atropine and require only brief hospitalization. Moderate to severe cases typically require twenty-four to seventy-two hours or longer of intensive care with continuous monitoring and repeated antidote dosing. Pralidoxime must be given early before aging of the enzyme-inhibitor complex occurs, typically within the first twenty-four hours. Dogs presenting late or with massive exposures have a more guarded prognosis. Cost of intensive care for severe organophosphate poisoning is substantial, and owners should receive honest counseling about both prognosis and expected expenses. Prevention of exposure through responsible pesticide use and storage is emphasized as far preferable to treating poisoning.

Recovery timeline for organophosphate toxicity varies from days to weeks depending on the severity of exposure and the specific compound involved. Dogs with mild poisoning that receive prompt treatment may recover within twenty-four to forty-eight hours as atropine controls muscarinic symptoms and the cholinesterase gradually regenerates. Moderate cases typically require three to seven days of recovery before returning to normal function. Severe poisoning may require one to four weeks or longer for full recovery, as new acetylcholinesterase must be synthesized to replace the irreversibly inhibited enzyme. Some dogs experience intermediate syndrome occurring three to five days post-exposure, characterized by proximal muscle weakness including respiratory muscles, requiring continued intensive support.

Post-treatment care requirements depend on the severity of the initial toxicity. Dogs discharged after mild poisoning need rest and monitoring at home with activity restriction for several days. Oral atropine or other medications may be prescribed for continued muscarinic symptom control in some cases. Multiple recheck appointments may be scheduled to monitor for delayed complications including intermediate syndrome or delayed peripheral neuropathy. Bloodwork including cholinesterase levels may be repeated to confirm enzyme recovery. Activity should be gradually increased as the dog's strength and stamina normalize. Any recurrence of symptoms warrants immediate veterinary contact.

Prognosis factors for organophosphate toxicity include the specific compound involved, as some organophosphates are more toxic than others and some age more rapidly to the irreversible enzyme-inhibitor complex. The dose absorbed relative to body weight significantly affects outcome. Time to treatment is critical, with dogs receiving antidotes within hours of exposure having far better prognoses than those presenting later. Severity of respiratory compromise is the most important determinant of survival in acute poisoning. Development of seizures worsens prognosis. Age and overall health status affect the dog's ability to withstand the metabolic stress of severe poisoning. Dogs that survive the acute phase generally have good long-term prognoses.

Long-term outlook for survivors of organophosphate toxicity is generally favorable once the acute crisis is resolved. Most dogs recover completely with no permanent neurological deficits. Acetylcholinesterase levels return to normal within weeks as new enzyme is synthesized. Some dogs may experience delayed peripheral neuropathy one to four weeks after exposure, characterized by weakness and sensory changes in the limbs, which may be permanent in some cases. Intermediate syndrome, if it occurs, resolves with supportive care over one to two weeks in most cases. Behavioral changes reported in some human survivors have not been well documented in dogs. The most important long-term consideration is preventing future exposures, which requires ongoing vigilance about pesticide use and storage in the dog's environment.

Primary prevention of organophosphate toxicity focuses on eliminating or minimizing exposure opportunities. Pet owners should carefully read labels on any pesticide, insecticide, or lawn care product before use to identify organophosphate ingredients. When possible, selecting non-organophosphate alternatives for pest control reduces risk. If organophosphates must be used, dogs should be kept indoors or away from treated areas until products have dried completely and for the duration specified on the label. Treated lawns should not be watered or walked on until the waiting period has passed. Professional applicators should be informed about pets, and pet owners should ask about the products being used.

Breeding and genetic factors do not influence susceptibility to organophosphate toxicity, but responsible pet ownership practices reduce exposure risk. All household pesticides should be stored in secure, locked cabinets inaccessible to pets. Spills should be cleaned immediately and thoroughly. Empty containers should be disposed of properly according to label directions, as residues can still be toxic. Pets should never be allowed to drink from puddles in areas where pesticides may have been applied. When visiting parks, farms, or unfamiliar outdoor areas, owners should remain alert to posted pesticide application notices and keep dogs leashed away from treated zones.

Nutritional considerations do not directly prevent organophosphate toxicity, but general health maintenance supports the body's ability to detoxify exposures. Dogs maintained at a healthy weight with adequate nutrition may have more robust hepatic metabolism. There are no supplements proven to prevent organophosphate toxicity or reduce severity if exposure occurs. The focus for prevention must remain on avoiding exposure rather than attempting to protect against it through dietary means.

Health maintenance practices relevant to organophosphate toxicity prevention include using veterinarian-approved flea and tick products rather than older organophosphate-based options that may still be available. Regular veterinary care ensures dogs are healthy and that any underlying liver conditions that might affect metabolism are identified. Knowing your local veterinary emergency facilities and poison control resources before any emergency occurs ensures rapid response if exposure happens. Maintaining accurate records of your dog's weight facilitates dose calculations if treatment is ever needed.

Early intervention when exposure is suspected is critical for the best outcomes. Any known or suspected contact with organophosphate products warrants immediate veterinary attention, even before symptoms develop. If dermal exposure has occurred, initiate bathing with dish soap and water while arranging veterinary care, taking precautions to protect yourself from exposure. Bring any product containers or labels to the veterinary visit to assist with identification. The ASPCA Animal Poison Control Center and Pet Poison Helpline can provide guidance while en route to emergency care. Do not wait for symptoms to develop, as treatment is most effective when given before significant cholinesterase inhibition has occurred.

Daily management for dogs recovering from organophosphate toxicity focuses on supporting complete recovery while preventing future exposures. During the recovery period, dogs may require continued medications including oral atropine if muscarinic symptoms persist. Activity should be restricted initially, as muscle weakness may make normal activities unsafe. Gradually increasing exercise over days to weeks allows monitoring for any persistent deficits. Fresh water and a complete, balanced diet support metabolic recovery. Close observation for any recurrence of symptoms or development of delayed complications such as intermediate syndrome guides decisions about when to seek follow-up veterinary care.

Home environment modifications are essential for preventing future organophosphate exposure. All pesticides and insecticides should be inventoried, and organophosphate products should be securely stored or responsibly disposed of. Non-toxic pest control alternatives should be explored with professional applicators. Communication with neighbors about lawn treatments helps anticipate potential exposure risks. If professional pesticide applications occur in the area, dogs should be confined indoors during and after treatment according to product label requirements. Creating pesticide-free zones where dogs exercise and play provides safer outdoor space.

Quality of life for dogs recovering from organophosphate toxicity is typically excellent once the acute crisis resolves. Most dogs return to their normal activities and temperament within days to weeks of the poisoning event. During recovery, providing comfortable resting areas, mental stimulation appropriate to energy levels, and gentle interaction supports both physical and emotional wellbeing. Dogs that experienced prolonged hospitalization may take some time to readjust to the home environment. As strength returns, gradual reintroduction of favorite activities, walks, and play helps confirm full recovery and rebuilds the bond between dog and owner that may have been strained during the crisis.

Monitoring and ongoing care requirements after organophosphate toxicity vary based on severity. Mild cases may need only a single recheck examination to confirm recovery. Moderate to severe cases benefit from repeated cholinesterase level measurements to document enzyme regeneration, typically returning to normal over two to six weeks. Owners should monitor for signs of intermediate syndrome occurring three to five days post-exposure, including renewed weakness particularly of the hindlimbs and respiratory muscles. Signs of delayed peripheral neuropathy one to four weeks later include weakness, abnormal gait, or decreased sensation in the limbs. Any concerning signs warrant prompt veterinary evaluation.

Caregiver support resources help owners cope with the stress and aftermath of organophosphate poisoning. Emergency veterinary care for severe poisoning is expensive, and financial assistance options such as CareCredit, Scratchpay, or charitable organizations like RedRover Relief may help. The experience of watching a beloved pet suffer through poisoning is traumatic, and owners should not hesitate to seek support from family, friends, or counselors. Channeling the experience into advocacy for safer pest control practices in the community benefits other pets. Connecting with other pet owners who have experienced poisoning emergencies provides understanding and practical advice. Most importantly, recognizing that accidents can happen despite best precautions helps owners move forward without excessive guilt.

Organophosphate toxicity can affect any dog regardless of breed, with no genetic predisposition identified. All dogs are susceptible to the toxic effects of organophosphates on acetylcholinesterase, and severity depends on dose relative to body weight rather than breed-specific factors. However, smaller breeds face higher relative risk because a given amount of toxin represents a proportionally larger dose. Toy and small breeds that encounter the same concentration of pesticide as larger dogs receive more toxin per kilogram of body weight, potentially resulting in more severe effects. This size consideration applies universally rather than to specific breeds.

Moderate-risk categories based on behavior and lifestyle include dogs that spend significant time in environments where organophosphates are used. Hunting dogs and field dogs that work in agricultural areas have increased exposure opportunities. Dogs with strong scavenging behaviors may be more likely to ingest contaminated materials. Curious dogs that investigate their environment extensively may contact treated surfaces or products. Dogs allowed off-leash in unfamiliar areas cannot be protected from unknown pesticide applications. Conversely, dogs kept primarily indoors, closely supervised during outdoor time, and exercised only in pesticide-free areas face lower exposure risk regardless of breed.

Screening recommendations for organophosphate toxicity differ from genetic health conditions because the risk is exposure-based rather than inherited. There is no genetic testing applicable to organophosphate sensitivity. Prevention focuses on eliminating or minimizing exposure through responsible pesticide use, secure storage, and vigilant supervision. All dog owners, regardless of breed, should familiarize themselves with the symptoms of cholinergic toxicity so they can recognize poisoning quickly if exposure occurs. Knowing the location of emergency veterinary services and having poison control contact information readily available applies to all households. Baseline cholinesterase levels could theoretically be measured in high-risk individuals, but this is not standard practice and the primary focus remains on prevention.

Commonly co-occurring conditions with organophosphate toxicity relate to the systemic effects of cholinesterase inhibition. Aspiration pneumonia may develop if dogs inhale oral secretions or vomitus during the period of excessive salivation and impaired consciousness. Respiratory failure is the primary life-threatening complication and may require mechanical ventilation. Seizures can cause secondary brain injury and hyperthermia if prolonged. Intermediate syndrome, occurring three to five days post-exposure, causes weakness of proximal limb and respiratory muscles. Delayed organophosphate-induced polyneuropathy may develop one to four weeks after exposure in some cases, causing sensory and motor deficits in the limbs. These conditions require specific management in addition to treating the underlying toxicity.

Conditions with similar symptoms to organophosphate toxicity include other causes of cholinergic excess. Carbamate insecticide poisoning produces nearly identical signs through the same mechanism of cholinesterase inhibition, though the inhibition is reversible and duration is shorter. Certain mushroom species containing muscarine cause salivation, urination, defecation, and lacrimation but without nicotinic effects. Pilocarpine or other cholinergic medication overdose can mimic organophosphate toxicity. Myasthenia gravis causes muscle weakness that might be confused with nicotinic effects. Distinguishing features include history of potential exposure, the full constellation of both muscarinic and nicotinic signs, depressed cholinesterase levels, and response to atropine.

Potential complications from organophosphate toxicity include those arising during the acute phase and delayed effects. Acute complications include aspiration pneumonia, respiratory failure requiring ventilation, seizure-related injury, hyperthermia, and rarely cardiac arrhythmias. Intermediate syndrome typically resolves with supportive care but can be fatal if respiratory support is inadequate. Delayed polyneuropathy may cause permanent weakness or sensory changes in some cases. Behavioral changes have been reported in human survivors and may occur in dogs, though documentation is limited. Chronic low-level organophosphate exposure in agricultural workers has been associated with neurobehavioral effects, raising theoretical concerns about residual effects in surviving dogs, though this has not been well studied in veterinary patients.